Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population

Janssen, a unit of Johnson & Johnson JNJ, released topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating Rybrevant (amivantamab-vmjw) regime versus chemotherapy alone, targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET).

The Rybrevant regime includes with and without lazertinib combined with chemotherapy (carboplatin and pemetrexed).

MARIPOSA-2 enrolled patients with locally advanced or metastatic EGFR exon 19 deletions (ex19del) or L858R substitution NSCLC after disease progression on or after AstraZeneca Plc's AZN Tagrisso (osimertinib). 

The study met its dual primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy alone in both experimental treatment arms. No new safety signals were found.

Janssen plans to submit these results for presentation at upcoming scientific congresses, including details on secondary endpoints such as overall survival, objective response, duration of response, and intracranial PFS.

A Rybrevant and lazertinib combination is also being evaluated in the first-line setting for patients with EGFR-mutated NSCLC in the Phase 3 MARIPOSA study. 

Price Action: JNJ shares are down 1.33% at $158.54 on the last check Wednesday.